布地奈德作用功效

It is a light beige solid chemical substance. The effects of budesonide: 1. Induces the synthesis of lipocortin and inhibits phospholipase A2, reducing the production and release of lipid inflammatory mediators such as platelet activating factor, leukotrienes, prostaglandins and other lipid inflammatory mediators generated by the hydrolysis of membrane phospholipids catalyzed by this enzyme. 2. Induce the expression of angiotensin I converting enzyme and neutral endopeptidase, respectively accelerate the production of angiotensin II, and degrade and inactivate bradykinin and tachykinin; inhibit the expression of nitrous oxide synthase and reduce the production of nitrous oxide. Thereby constricting blood vessels, or reducing the effects of various other active substances other than vasotensin II on dilating blood vessels, causing inflammation, and inducing neurogenic inflammatory reactions. In addition, it can also induce the production of the vasoconstrictor substance angiocortin.

3. Inhibit the expression of various cytokines, such as interleukins 1, 3, 4, 6, and 8, tumor necrosis factor, and granulocyte colony-stimulating factor. Reduce the role of the above factors in airway inflammation, especially chronic inflammation. 4. Promote the expression of adrenergic β2 receptors and increase sensitivity to endogenous and exogenous medicinal β2 receptor agonists. 5. Immunosuppressive effect: It has an inhibitory effect on the entire immune process from the phagocytosis of antigens, the division, proliferation and differentiation of lymphocytes to the effector period.

Recommended dosage for the treatment of mildly to moderately active Crohn's disease: Adults: 9 mg daily for up to 8 weeks; repeat 8-week course of treatment with recurrent episodes of active disease. Pediatrics 8 to 17 years weighing more than 25 kg: 9 mg once daily for up to 8 weeks, then 6 mg once daily for 2 weeks. Budesonide dosage to maintain clinical remission in mild to moderate Crohn's disease: Adults: 6 mg daily for up to 3 months; discontinue after 3 months of completion of tapering. Continuation of treatment beyond 3 months has not been shown to provide substantial clinical benefit. When switching from oral prednisolone, begin tapering the prednisolone dose and simultaneously initiate budesonide.